Skip to main content
Addgene

PB-TRE-dCas9-VPR-pA-3xsgRNA-EF1a-Tet.O-T2A-PuroR-polyA
(Plasmid #166693)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 166693 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    PiggyBac
  • Backbone size w/o insert (bp) 7250
  • Total vector size (bp) 14555
  • Vector type
    Mammalian Expression, CRISPR
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert 1

  • Gene/Insert name
    dCas9-VPR
  • Species
    Streptococcus pyogenes
  • Insert Size (bp)
    7300
  • Promoter TRE

Cloning Information for Gene/Insert 1

  • Cloning method Restriction Enzyme
  • 5′ cloning site Eco105I (not destroyed)
  • 3′ cloning site NotI (not destroyed)
  • 5′ sequencing primer cgtaccacttcctaccctcg
  • (Common Sequencing Primers)

Gene/Insert 2

  • Gene/Insert name
    3x Cnga1 promoter-targeting sgRNAs
  • Species
    Streptococcus pyogenes
  • Promoter U6

Cloning Information for Gene/Insert 2

  • Cloning method Restriction Enzyme
  • 5′ cloning site XmaJI (not destroyed)
  • 3′ cloning site PacI (not destroyed)
  • 5′ sequencing primer GCGGCAGGCCCTGCCATAGC
  • 3′ sequencing primer ACACAAAAAACCAACACACAGA
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    PB-TRE-dCas9-VPR-pA-3xsgRNA-EF1a-Tet.O-T2A-PuroR-polyA was a gift from Elvir Becirovic (Addgene plasmid # 166693 ; http://n2t.net/addgene:166693 ; RRID:Addgene_166693)
  • For your References section:

    A gene therapy for inherited blindness using dCas9-VPR-mediated transcriptional activation. Bohm S, Splith V, Riedmayr LM, Rotzer RD, Gasparoni G, Nordstrom KJV, Wagner JE, Hinrichsmeyer KS, Walter J, Wahl-Schott C, Fenske S, Biel M, Michalakis S, Becirovic E. Sci Adv. 2020 Aug 19;6(34):eaba5614. doi: 10.1126/sciadv.aba5614. eCollection 2020 Aug. 10.1126/sciadv.aba5614 PubMed 32875106